Genes and hepatitis C: Susceptibility, fibrosis progression and response to treatment

Liver International

Volumn 31, Issue 4, 2011, Pages 443-460

  Romero Gomez, Manuel ^a   Eslam, Mohamed ^a   Ruiz, Agustín ^b   Maraver, Marta ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Neocodex   (Spain)

Author keywords

Fibrosis; Progression; Spontaneous viral clearance; Sustained response

Indexed keywords

HLA ANTIGEN CLASS 2; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ALLELE; DISEASE COURSE; DISEASE SEVERITY; DNA FINGERPRINTING; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEREDITY; HUMAN; INFLAMMATION; IRON METABOLISM; LIVER FIBROSIS; META ANALYSIS; PROMOTER REGION; REVIEW; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS C; HLA ANTIGENS; HUMANS; INTERFERON ALFA-2B; INTERLEUKINS; LIVER CIRRHOSIS; ODDS RATIO; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN;

EID: 79952463034     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02449.x     Document Type: Review

References (137)

1. Morin T, Pariente A, Lahmek P, et al. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010; 22: 157-66.
2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
3. Li Q, Brass AL, Ng A, et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci USA 2009; 106: 16410-5.
4. Zhang FR, Huang W, Chen SM, et al. Genome wide association study of leprosy. N Engl J Med 2009; 361: 2609-18.
5. Mira MT, Alcaïs A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004; 427: 636-40.
6. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-7.
7. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
8. Sakuntabhai A, Turbpaiboon C, Casadémont I, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005; 37: 507-13.
9. Jallow M, Teo YY, Small KS, et al. Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet 2009; 41: 657-65.
10. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-5.
11. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39: 523-8.
12. Alric L, Fort M, Izopet J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-81.
13. Hong X, Yu RB, Sun NX, et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2005; 11: 7302-7.
14. Kuniholm MH, Kovacs A, Gao X, et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 2010; 51: 1514-22.
15. Höhler T, Kruger A, Gerken G, et al. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-7.
16. Chen Y, Pei J. An assessment of a TNF polymorphic marker for the risk of HCV infection: meta-analysis and a new clinical study design. Infect Genet Evol 2009; 9: 1356-63.
17. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol 2010; 8: e1000294.
18. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-4.
19. Knapp S, Warshow U, Hegazy D, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010; 51: 1168-75.
20. Zúñiga J, Romero V, Azocar J, et al. Protective KIR-HLA interactions for HCV infection in intravenous drug users. Mol Immunol 2009; 46: 2723-7.
21. Montes-Cano MA, Caro-Oleas JL, Romero-Gómez M, et al. HLA-C and KIR genes in hepatitis C virus infection. Hum Immunol 2005; 66: 1106-9.
22. Constantini PK, Wawrzynowicz-Syczewska M, Clare M, et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404-12.
23. Lio D, Caruso C, Di Stefano R, et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003; 64: 674-80.
24. Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212-8.
25. Mangia A, Santoro R, Piattelli M, et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004; 25: 103-9.
26. Mueller T, Mas-Marques A, Sarrazin C, et al. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004; 41: 652-8.
27. Houldsworth A, Metzner M, Rossol S, et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 2005; 25: 271-6.
28. Oleksyk TK, Thio CL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005; 6: 347-57.
29. Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006; 80: 9144-50.
30. Hennig BJ, Frodsham AJ, Hellier S, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007; 27: 1134-43.
31. An P, Thio CL, Kirk GD, et al. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis 2008; 198: 1159-65.
32. Minton EJ, Smillie D, Smith P, et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol 2005; 66: 127-32.
33. Kusumoto K, Uto H, Hayashi K, et al. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006; 34: 24-31.
34. Kakumu S, Okumura A, Ishikawa T, et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997; 109: 458-63.
35. Kimura T, Saito T, Yoshimura M, et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006; 193: 1371-4.
36. Schott E, Witt H, Hinrichsen H, et al. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol 2007; 46: 372-80.
37. Wietzke-Braun P, Maouzi AB, Mänhardt LB, et al. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006; 18: 991-7.
38. Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008; 28: 141-52.
39. Mascheretti S, Hinrichsen H, Ross S, et al. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol 2004; 136: 328-33.
40. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54: 1157-61.
41. Elsammak MY, Al-Sharkaweey RM, Ragab MS, Amin GM, Kandil MH. In Egyptians, a mutation in the lymphotoxin-alpha gene may increase susceptibility to hepatitis C virus but not that to schistosomal infection. Ann Trop Med Parasitol 2008; 102: 709-16.
42. Tena-Tomás C, de Messias-Reason I, Song le H, et al. A globally occurring indel polymorphism in the promoter of the IFNA2 gene is not associated with severity of malaria but with the positivity rate of HCV. BMC Genet 2008; 9: 80.
43. Huang Y, Yang H, Borg BB, et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007; 104: 985-90.
44. Bekker V, Chanock SJ, Yeager M, et al. Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. J Viral Hepat 2010; 17: 192-200.
45. Hennig BJ, Hellier S, Frodsham AJ, et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002; 3: 359-67.
46. Mas Marques A, Mueller T, Welke J, et al. Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infect Genet Evol 2009; 9: 847-52.
47. Zhu C, Zhang R, Liu D, et al. Association of functional polymorphism of ApoB promoter with hepatitis C virus infection. Clin Chim Acta 2009; 401: 124-7.
48. Owen DM, Huang H, Ye J, Gale M Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108.
49. Benga WJ, Krieger SE, Dimitrova M, et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 2010; 51: 43-53.
50. Wozniak MA, Itzhaki RF, Faragher EB, et al. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456-63.
51. Price DA, Bassendine MF, Norris SM, et al. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 2006; 55: 715-8.
52. Ferré N, Marsillach J, Camps J, et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin Chim Acta 2005; 361: 206-10.
53. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
54. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
55. Montes-Cano M, García-Lozano JR, Abad-Molina C, Romero-Gómez M. IL28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-7.
56. Rauch A, Kutalik Z, Descombes P. Genetic variation in IL28B is associated with chronic hepatitis C and treatment Failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
57. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
58. National Institute of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36 (Suppl. 1): S3-20.
59. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
60. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503.
61. Kryczka W, Brojer E, Kalinska A, et al. DRB1 alleles in relation to severity of liver disease in patients with chronic hepatitis C. Med Sci Monit 2001; 7 (Suppl. 1): 217-20.
62. Tillmann HL, Chen DF, Trautwein C, et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001; 48: 714-8.
63. Renou C, Halfon P, Pol S, et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-90.
64. Hue S, Cacoub P, Renou C, et al. Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 2002; 186: 106-9.
65. Patel K, Norris S, Lebeck L, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006; 43: 241-9.
66. Morgan T R, Lambrecht RW, Bonkovsky HL, et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008; 49: 548-56.
67. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38: 1468-76.
68. Ruiz-Ferrer M, Barroso N, Antinolo G, et al. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies. J Viral Hepat 2004; 11: 319-23.
69. Goyal A, Suneetha PV, Kumar GT, et al. CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12: 4721-6.
70. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124: 352-60.
71. Muhlbauer M, Bosserhoff AK, Hartmasnn A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125: 1085-93.
72. Glas J, Torok HP, Tonenchi L, et al. The-2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology 2004; 126: 1930-2.
73. Bonkovsky HL, Salek J. No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C [Correspondence]. Gastroenterology 2005; 128: 1361-2.
74. Sermasathanasawadi R, Kato N, Muroyama R, et al. Association of IRF-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients. Liver Int 2008; 28: 798-806.
75. Colina R, Costa-Mattioli M, Dowling RJ, et al. Translational control of the innate immune response through IRF-7. Nature 2008; 452: 323-8.
76. Leroy V, Vigan I, Mosnier JF, et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003; 38: 829-41.
77. Apolinario A, Majano PL, Alvarez-Perez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97: 2861-70.
78. Hofer H, Neufeld JB, Oesterreicher C, et al. Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. Genes Immun 2005; 6: 242-7.
79. Abbas Z, Moatter T, Hussainy A, et al. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005; 11: 6656-61.
80. Gao QJ, Liu DW, Zhang SY, et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009; 15: 5610-19.
81. Manohar K, Suneetha PV, Sukriti, et al. Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol Int 2009; 3: 371-7.
82. Bouzgarrou N, Hassen E, Schvoerer E, et al. Association of Interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 2008; 80: 607-14.
83. Suneetha PV, Goyal A, Hissar SS, et al. Studies on TAQ1 polymorphism in the 30 untranslated region of IL-12P40 gene in HCV patients infected predominantly with genotype 3. J Med Virol 2006; 78: 1055-60.
84. Dai CY, Chuang WL, Lee LP, et al. Associations of tumour necrosis factor alpha promoter polymorphisms at position 308 and -238 with clinical characteristics of chronic hepatitis C. J Viral Hepat 2006; 13: 770-4.
85. Yu ML, Dai CY, Chiu CC, et al. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003; 59: 35-40.
86. Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386-90.
87. Wozniak MA, Itzhaki RFTrent HCV Study Group et al. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456-63.
88. Dai CY, Chuang WL, Hsieh MY, et al. Polymorphism of interferon-gamma gene at position 1874 and clinical characteristics of chronic hepatitis C. Transl Res 2006; 148: 128-33.
89. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4: 411-9.
90. Li CZ, Kato N, Chag JH, et al. Polymorphism of OAS-1determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int 2009; 29: 1413-21.
91. Brown KS, Keogh MJ, Tagiuri N, et al. Severe fibrosis in hepatitis C virus infected patients is associated with increased activity of the mannan-binding-lectin (MBL)/MBL-associatedserine protease 1 (MASP-1) complex. Clin Exp Immunol 2007; 147: 90-8.
92. Alves Pedroso ML, Boldt A B, Pereira-Ferrari L, et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin Exp Immunol 2008; 152: 258-64.
93. Yee LJ, Tang YM, Kleiner DE, et al. Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology 2007; 46: 74-83.
94. Diwakaran HH, Befeler AS, Britton RS, et al. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36: 687-91.
95. Martinelli AL, Ramalho LN, Zucoloto S. Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol 2004; 19: 91-8.
96. Negro F, Samii K, Rubbia-Brandt L, et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000; 60: 21-7.
97. Pirisi M, Scott CA, Avellini C, et al. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000; 113: 546-54.
98. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248-52.
99. Erhardt A, Maschner-Olberg A, Mellenthin C, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrosis. J Hepatol 2003; 38: 335-42.
100. Tung BY, Emond MJ, Bronner MP. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124: 318-26.
101. Romero Gómez M, Castellano Megias VM, Sanchez-Muñoz D, et al. Factores agravantes de la lesión hepática en la hepatitis C. Rev And Pat Digest 2002; 25: 178-83.
102. Gehrke SG, Stremmel W, Mathes I, et al. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. J Mol Med 2003; 81: 780-7.
103. Bonkovsky HL, Troy N, McNeal K, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002; 37: 848-54.
104. Romero-Gomez M, Montes-Cano M A, Otero-Fernanadez MA, et al. SLC11a1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut 2004; 53: 446-50.
105. Garcia L, Hernandez I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002; 37: 797-805.
106. Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002; 316: 83-94.
107. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
108. Pereira FA, Pinheiro da Silva NN, Rodart IF, et al. Association of TGF-1 Codon 25 (G915C) Polymorphism with hepatitis C virus infection. J Med Virol 2008; 80: 58-64.
109. Armendariz-borunda J, Rincón AR, Muñoz-Valle JF. Fibrogenic polymorphisms (TGF-β, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J Invest Med 2008; 56: 944-53.
110. Poujol-Robert A, Rosmorduc O, Serfaty L, et al. Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 2004; 99: 527-31.
111. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52: 1206-10.
112. Poujol-Robert A, Boelle PY, Poupon R, et al. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology 2004; 39: 1174-5.
113. Martinelli A, Knapp S, Worku M. Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver Fibrosis. J Gastroenterol Hepatol 2008; 23: 1403-9.
114. Reynolds WF, Patel K, Pianko S, et al. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. Genes Immun 2002; 3: 345-9.
115. Thio CL. Host Genetic Factors and Antiviral Immune Responses to Hepatitis C Virus. Clin Liver Dis 2008; 12: 713-26.
116. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 1679-87.
117. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306.
118. Li Y, Chang M, Abar O, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009; 51: 750-7.
119. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50: 1038-44.
120. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
121. Asahina Y, Izumi N, Uchihara M, et al. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol 2003; 39: 421-7.
122. Suzuki F, Arase Y, Suzuki Y, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004; 11: 271-6.
123. Mueller T, Gessner R, Sarrazin C, et al. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology 2003; 38: 1592.
124. Schiemann U, Glas J, Torok P, et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 2003; 68: 1-4.
125. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271-7.
126. Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-12.
127. Romero-Gomez M, Gonzalez-Escribano MF, Torres B, et al. HLA class I B44 is associated with sustained response to interferon+ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol 2003; 98: 1621-6.
128. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
129. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
130. Asselah T, Essioux L, Marcellin P, et al. A chromosome 19 SNP (rs12979860) predicts outcome (EVR/SVR) in HCV patients treated with interferon, independent of pegylation or ribavirin. J Hepatol 2010; 52: 1180A.
131. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
132. Del Campo JA, Maraver M, Pardo B, et al. Genome-wide association and high throughput genotype imputation studies confirm a susceptibility locus to HCV infection on 6p22.1-p21.31. J Hepatol 2010; 52: 644A.
133. Thompson AJ, Muir AJ, Sulkowski MS, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 2010; 139: 120-9.
134. Mangia A, Tompson A, Santoro R, et al. Predictive role of IL28B C/C genotype on SVR and RVR in patients with genotype 2/3 chronic infection. Gastroenterology 2010; 139: 821-7.
135. Stättermayer AF, Stauber R, Hofer H, et al. Impact of the IL28B-genotype on early and sustained virologic response in treatment-naïve patients with chronic hepatitis C treated with Peg-Interferon-α2a and Ribavirin. Clin Gastroenterol Hepatol 2010. DOI: DOI: 10.1016/j.cgh.2010.07.019.
136. Gad HH, Dellgren C, Hamming OJ, et al. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284: 20869-75.
137. Iadonato SP, Katze MG. Genomics: hepatitis C virus gets personal. Nature 2009; 461: 357-8.